Biotech Company To Federal Circuit: Rehearing Needed For DNA Eligibility
WASHINGTON, D.C. — The maker of a gene therapy product is seeking en banc rehearing of a Federal Circuit U.S. Court of Appeals finding that a Delaware federal judge wrongly concluded...To view the full article, register now.
Already a subscriber? Click here to view full article